Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on September 24, 2021. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and governance rather than financial performance.
Compensation Details for New Director:
- Cash Compensation: $40,000 per year for Board service; $4,000 per year for Nominating Committee service.
- Equity Grant: 10-year non-qualified stock option to purchase 44,000 shares of common stock.
- Exercise Price: Equal to the closing price on the Grant Date (October 1, 2021).
- Vesting Schedule: Equal annual installments over three years, with the first tranche vesting on October 1, 2022.
Material Changes
The Board of Directors increased its size from five to six members. Ran Zheng was appointed as a Class I director and assigned to the Nominating and Corporate Governance Committee. No other material financial or operational changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific business risks. It notes that Ms. Zheng entered into a standard indemnification agreement and confirms there are no undisclosed arrangements or family relationships with other directors or officers.
Investor Verification Checklist
- Verify the closing stock price on October 1, 2021, to determine the exercise price of the 44,000 share option granted to Ms. Zheng.
- Review the Company's 2021 Equity Incentive Plan to understand the full terms of the equity awards.
- Confirm the total number of authorized shares and the impact of this new grant on potential dilution.
- Check subsequent filings for the formal press release referenced as Exhibit 99.1 for additional context on the appointment.